Also, the two classes of drugs with glucose-independent protective effects against diabetic MVC, namely glucagon-like peptide 1 (GLP-1) receptor agonists [47] and sodium-glucose co-transporter 2 (SGLT-2) inhibitors [48], were approved in T2D in 2005 and 2013, respectively, and became widely used only later. This evidence concerns the gene GCG and type 2 diabetes mellitus.